tobramycin
treatment
infection
due
pseudomonas
aeruginosa
patient
cystic
fibrosis
effectiveness
safety
tobramycin
infection
due
pseudomonas
aeruginosa
patient
cystic
fibrosis
studied
patient
moderate
severe
exacerbation
chronic
pulmonary
infection
seventeen
course
treatment
given
tobramycin
mg
kg
per
day
administered
intravenously
three
divided
dos
per
day
seven
day
specimen
sputum
yielded
moderate
heavy
growth
p
aeruginosa
isolates
inhibited
mug
tobramycin
ml
seven
case
isolates
inhibited
mug
gentamicin
ml
mean
level
tobramycin
blood
mug
ml
hr
mug
ml
hr
administration
patient
received
antistaphylococcal
agent
therapy
patient
except
two
received
mg
carbenicillin
kg
per
day
intravenously
six
divided
dos
g
carbenicillin
mask
inhalation
three
time
day
clinical
radiological
improvement
noted
patient
white
blood
cell
count
elevated
seven
patient
returned
normal
level
blood
gas
improved
p
aeruginosa
eliminated
sputum
five
case
adverse
side
effect
noted
